Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Sercan Aksoy


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


S. Aksoy1, R.F. Degirmenciler2, B.Y. Aktas1, D.C. Guven1, O.H. Aktepe1, G. Guner1, H. Taban1, N. Kertmen1, Z. Arik1, O. Dizdar1

Author affiliations

  • 1 Department Of Medical Oncology, Hacettepe University Faculty of Medicine, 6100 - Ankara/TR
  • 2 Department Of Internal Medicine, Hacettepe University Faculty of Medicine, 6100 - Ankara/TR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4110


Impaired DNA damage response (DDR) mechanisms and subsequent genomic instability is associated with carcinogenic process itself, but it also results in sensitivity of tumor cells to certain drugs and can be exploited to treat cancer by inducing deadly mutations or mitotic catastrophe. As a result, BRCA1/2 testing is recommended for a group individuals with breast/ovarian cancer.


In this study, we retrospectively invesitigated clinicopathologic features of 303 breast cancer patients tested for BRCA 1/2 mutation in an oncology institute. NCCN recommendations are used to select patients to be tested for BRCA mutations.


A total of 303 patients were analysed for BRCA 1/2 mutations. Median age of the patients at diagnoses were 40 (21-65). Family history for BRCA related cancers were detected in 120 patients (39.6%). BRCA 1/2 mutations have been shown in 98 of 303 patients (32.3%). Of 98 BRCA mutated patients, 43 had pathogenic BRCA1 mutation, 39 had pathogenic BRCA2 mutation, 11 had variant of uncertain significance (VUS) BRCA2 mutation, 3 had VUS BRCA1 mutation and 2 had pathogenic BRCA1 and 2 mutations. Molecular subtypes of tumors have been shown in Table.Table:

316P Molecular subtypes of tumors

BRCA StatusHR(+)/ HER2(-), N(%)HR(+)/ HER2(+), N(%)HR(-)/ HER2(+), N (%)Triple(-), N (%)N/A,N(%)
BRCA118 (41.8%)2 (4.6%)022 (51.1%)1 (2.3%)
BRCA225 (64.1%)3 (7.7%)06 (15.3%)5 (12.8%)
BRCA1 VUS2 (66.7%)001 (33.3%)0
BRCA2 VUS11 (100%)0000
BRCA1 + 201 (50%)01 (50%)0
BRCA mut (-)126 (61.4%)25 (12.1%)12 (5.8%)32 (15.6%)10 (4.8%)
TOTAL182 (60%)31 (10.2%)12 (3.9%)62 (20.4%)16 (5.2%)

Twelve of 98 BRCA mutated patients (12.2%) were de novo metastatic while 15 patients (15.3%) faced with metastatic disease during follow-up. In the BRCA mutated group there was significantly high rate of metastatic disease has been detected comparing BRCA non-mutated group (27.5% vs %16.5% respectively, p = 0.026). Metastatic BRCA mutant patients showed worse OS numerically but data is not statistically significant (P = 0.894). Nine patients were diagnosed with contralateral breast cancer, and 3 patients was diagnosed with BRCA-related cancers during follow-up. Prophylactic surgery (contralateral mastectomy and/or oophorectomy) was performed in 32 of 98 patients.


According to this retrospective study, BRCA mutant patients tend to have worse clinical and pathological features comparing age-matched controls.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sercan Aksoy.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.